FDA approves first anti-inflammatory drug for broad cardiovascular indication.
TL;DR
The FDA has approved colchicine, marketed as Lodoco, as the first anti-inflammatory medication to treat cardiovascular disease (CVD). Studies have shown that the drug can reduce the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for CVD. The drug was shown to reduce the risk of cardiac events by 31% on top of statin medications, the current standard of care. Colchicine is expected to be available for prescription in the US in the second half of 2023.
- FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease Cardiovascular Business
- FDA approves drug to reduce cardiac events Good Morning America
- FDA OKs Low-Dose Colchicine for Broad CV Indication Medscape
- U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease Business Wire
- FDA approves Agepha's version of colchicine for heart disease FiercePharma
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Cardiovascular Business